Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Frontiers in Oncology|April 17, 2020
Metabolic Reprogramming in Triple-Negative Breast CancerXiangyu Sun, Mozhi Wang, Mengshen Wang, et al.
Translational Cancer Research|February 4, 2022
Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?-a meta-analysis of randomized controlled trialsHaoran Dong, Litong Yao, Mozhi Wang, et al.
Cellular Signalling|October 12, 2023
PROS1, a clinical prognostic biomarker and tumor suppressor, is associated with immune cell infiltration in breast cancer: A bioinformatics analysis combined with experimental verificationTianyi He, Xiangyu Sun, Chen Wu, et al.
Translational Cancer Research|February 4, 2022
Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancerMengshen Wang, Mozhi Wang, Zhenning Wang, et al.
Oncogene|October 16, 2023
KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancerLitong Yao, Qian Hao, Mozhi Wang, et al.
Theranostics|June 23, 2021
HIF-1-induced mitochondrial ribosome protein L52: a mechanism for breast cancer cellular adaptation and metastatic initiation in response to hypoxiaXinyan Li, Mengshen Wang, Su Li, et al.
Frontiers in Cell and Developmental Biology|August 9, 2020
Role of Proton-Coupled Monocarboxylate Transporters in Cancer: From Metabolic Crosstalk to Therapeutic PotentialXiangyu Sun, Mozhi Wang, Mengshen Wang, et al.
Cancer Biology & Medicine|October 11, 2021
The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world studyLitong Yao, Zhiyuan Pang, Mozhi Wang, et al.
Frontiers in Oncology|May 14, 2021
An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector MachineMozhi Wang, Zhiyuan Pang, Yusong Wang, et al.
Signal Transduction and Targeted Therapy|May 25, 2025
Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trialQiang Zhang, Mozhi Wang, Yumeng Li, et al.
Pageof 3